The latest developments in Europe regarding plant extracts are of particular importance to all stakeholders in the hemp, CBD, and, more broadly, botanical product sectors. With the new European opinion on extracts, the message is quite clear: when an extract has no history of safe use in the European Union prior to 1997, it may fall under the category of novel food and require a thorough scientific evaluation. For consumers, this may seem highly technical, but in reality, the issue is simple: to better regulate what enters the market in order to limit health risks.
For savvy sellers, importers, and buyers, this notice isn't just about paperwork. It also has a tangible impact on cross-border trade, logistics, customs controls, and even, indirectly, roadside checks. In a CBD market where compliance, lab tests, and traceability make all the difference, understanding this new framework helps to better distinguish legitimate products from risky offers or those that seem too good to be true.
A new European opinion on extracts that changes the landscape
EFSA has long pointed out that plant extracts may fall under the novel food framework when they do not have a history of safe consumption in the EU before 1997. This clarification is far from anecdotal: it lays down an important legal and scientific basis for many hemp-based products, especially when their extraction process, concentration or food use deviates from traditionally known forms.
A recent example clearly illustrates this trend. On March 30, 2026, the EFSA published an opinion on the safety of a CO₂ extract of Cannabis sativa L. as a novel food, at the request of the European Commission. This type of opinion does not automatically mean that a product is prohibited or authorized in all cases, but it confirms that the authorities want to closely examine its composition, conditions of use, exposure levels, and potential toxicological risks.
In other words, the new European opinion on extracts serves as a strong signal for the market. Operators should expect more requests for proof of safety, technical documents, and analytical data. For reputable brands, it's also an opportunity: to promote tested products that comply with European law and are more defensible in the event of an inspection.
Why health and safety remains at the heart of the issue
From a public health perspective, the European approach remains clearly based on scientific expertise and controls. The EU has a robust system for preparing for and responding to food safety incidents, and EFSA can intervene at the request of the Commission, the ECDC, or national authorities when an incident has a multinational dimension. The idea, therefore, is not to wait for a problem to erupt, but to reduce risks upstream.
EFSA also reiterates a crucial point: foodborne illnesses can result from fraud, inadequate controls, or accidents. In this context, an opinion on extracts is part of a preventative approach. This approach is particularly relevant when dealing withplant extracts , as a product can accumulate not only desirable compounds but also undesirable contaminants if the raw materials or the processing method are not properly controlled.
For the end consumer, this reinforces the importance of choosing products accompanied by analysis reports, a clear composition, and a traceable origin. In the world of CBD and next-generation cannabinoids, the difference between a clean product and a risky one is not visible to the naked eye. This is precisely why scientific opinions and regulatory controls are becoming so crucial.
Agricultural extracts, pesticides and contaminants: a concrete point of concern
Extracts derived from agricultural raw materials are particularly sensitive to the issue of residues. In 2026, EFSA published data showing that out of 39,433 samples of imported food, 38.3% had no quantifiable residues. Of the remaining samples, 3.6% were non-compliant. These figures reveal two things: many products are acceptable, but a significant proportion still pose a problem.
The signal is also visible in the 2024 report on pesticide residues published by EFSA in 2026. Of the 9,842 samples analyzed in the coordinated program, 1.2% were found to be non-compliant. This percentage may seem small, but for concentrated extracts, the issue takes on a different dimension. When a plant contains undesirable traces, the extraction process can sometimes also concentrate certain contaminants if it does not include effective purification steps.
In the case of hemp-based products, this point deserves particular attention. Consumers often seek potent and well-defined oils, resins, or extracts. But the more technical a product is, the more important the rigor of the sourcing, analyses, and good manufacturing practices becomes. The new European opinion on extracts therefore reinforces an already logical requirement: quality must not only be claimed, it must be proven.
A direct impact on trade and market access
From a commercial perspective, the likely consequence is quite clear: more evidence of safety will be required for certain extracts. When EFSA deems a scientific safety opinion necessary for botanicals or extracts without prior safe use in the EU, this can inevitably lengthen market access times. Compiling a robust dossier requires time, data, and often a significant budget.
For businesses, this means higher compliance costs, especially for operators importing extracts or relying on innovative formulations. More detailed documentation will be required regarding composition, potential contaminants, authorized use, stability, and sometimes even consumption conditions. The most reputable companies may gain a competitive advantage, but opportunistic players will find it harder to keep up.
For customers, this tightening of standards isn't necessarily bad news. Yes, some products may become rarer or arrive on the market more slowly. But in return, the selection process tends to become more reliable. In a sector where quality varies enormously from one seller to another, a more demanding framework can help secure the supply and reduce the presence of questionable products.
Imports 2026: Enhanced border controls
In 2026, the European Commission announced a task force dedicated to improving the effectiveness of import controls. The focus is particularly on pesticide residues, food and feed safety, and animal welfare. While not all hemp extracts fall under the exact same regulatory categories, the general trend is clear: imported goods will be subject to more rigorous scrutiny.
The Commission also indicated that it would increase its export-related audits in third countries by 50% over two years, starting on January 1, 2026. This directly impacts international supply chains. Non-EU producers wishing to sell to the European market will have to more rigorously demonstrate their compliance, good practices, and process control.
For importers of extracts, this evolution may translate into more document checks, more targeted analyses, and a greater risk of being blocked in the event of an incomplete file. In practice, this favors transparent supply chains, well-traceable batches, and long-term partnerships with reliable suppliers. Opportunistic purchases, on the other hand, become riskier from both an economic and regulatory standpoint.
E-commerce, marketplaces and the explosion in volume to be controlled
E-commerce is significantly increasing the pressure on authorities. In its report published on July 20, 2026, the Commission indicated that in 2025, approximately 6 billion items were placed on the market, three times more than in 2022. At the same time, the EU's inspection rate fell to 65 items per million imported. This gap between volume and inspection capacity explains why the Union is seeking to strengthen its tools and better target risks.
This issue directly concerns online buyers of CBD and extracts. When a market explodes, compliant products coexist with mislabeled, incorrectly dosed, or outright illegal items. The French Directorate General for Competition Policy, Consumer Affairs and Fraud Control (DGCCRF) reported on April 29, 2026, that 46% of products analyzed on foreign marketplaces were non-compliant and dangerous, with over 100,000 products withdrawn from the market. The warning is very clear.
For consumers, the lesson is simple: price alone should never be the primary criterion. A specialized shop, transparent about its analyses, the origins of its products, and their compliance, generally offers a much higher level of security than an anonymous marketplace. As the new European opinion on extracts becomes part of the regulatory landscape, sellers able to demonstrate their reliability will have every incentive to highlight this compliance.
What is the connection with roadside checks in Europe?
At first glance, roadside checks may seem far removed from scientific analysis of extracts. In reality, the link is indirect but very real. Once imported or produced, extracts, oils, flowers, resins, or ingredients travel by road between logistics platforms, wholesalers, processors, and retailers. The EU is precisely seeking to harmonize the application of transport rules to ensure a level playing field and non-discriminatory enforcement in all Member States.
The Commission reiterates that the minimum number of joint checks between enforcement authorities of Member States is six per year. This coordination of checks contributes to a more uniform and effective application of transport rules. For operators, this means that documentary compliance, goods identification, batch traceability, and adherence to logistics rules are becoming increasingly important, especially for cross-border flows.
In practice, if regulations on extracts become stricter and imports are more closely monitored, transporters and distributors will also have to be beyond reproach. A poorly documented, incorrectly declared, or transported batch without sufficient supporting documentation can raise red flags during an inspection. Thus, a continuum emerges between scientific advice, border controls, the movement of goods, and their placement on the final market.
The official 2026 program confirms a logic of vigilance across the entire chain
The official control framework for the agri-food chain in 2026 follows the same approach. The Commission's implementing decision for the 2026 annual control program sets priorities on the safety of products of animal origin, food contact materials, residues of pharmaceutical substances, pesticides and contaminants, as well as preparedness for health crises. While not all hemp-based products fall into a single category, the overall philosophy is one of cross-cutting monitoring.
This comprehensive approach is important for extracts because their compliance does not depend on a single criterion. Regulatory status, toxicological safety, microbiological quality, residual solvents (if any), pesticides, labeling consistency, and the intended use of the product must all be considered. A fragmented view is no longer sufficient in a European market that seeks better integration between science, customs, official controls, and enforcement on the ground.
For well-structured professionals, this evolution can be a real boost to credibility. The more precise the framework, the more opportunities it becomes to differentiate oneself through reliable certificates of analysis, audited suppliers, and clear customer information. In CBD, as elsewhere, compliance is no longer just a defensive obligation; it's also a key selling point that inspires trust.
Ultimately, the new European opinion on extracts marks a significant milestone for the sector. It confirms that plant extracts, particularly innovative or concentrated ones, can no longer be treated as mere commodities. Food safety, scientific evidence, contaminant control, import compliance, and logistical traceability are now all interconnected. For the CBD and cannabinoid market, this translates into greater professionalization.
For adult consumers in France and Europe, the good news is that a more demanding regulatory framework can also mean better-controlled and more reliable products. For reputable retailers, the challenge is to turn this constraint into an advantage: offering legal, laboratory-tested, and clearly documented products. In a world where health inspections, online commerce, and road traffic are increasingly intersecting, transparency is clearly the best course of action.
